Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CLVS $23.03 4.9300 +27.24%
KERX $4.69 0.2700 +6.11%
OHRP $2.81 0.1500 +5.64%
GTXI $0.60 0.0300 +5.26%
PTLA $20.05 0.8300 +4.32%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

SPHS $3.89 -1.9300 -33.16%
CVM $0.50 -0.0352 -6.61%
TSRO $92.76 -6.3300 -6.39%
ADXS $13.35 -0.8400 -5.92%
THLD $0.97 -0.0500 -4.90%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | Next > | Last >>

Keytruda Cleared In Europe For Lung Cancer

(PMLiVE [UK]) Aug 3, 2016 - New second-line indication for Merck’s drug puts it in direct competition with BMS’ Opdivo.
read article 



US Breakthrough Status For Novartis’ Breast Cancer Drug

(PharmaTimes [UK]) Aug 3, 2016 - Novartis' experimental selective cyclin dependent kinase inhibitor LEE011 (ribociclib) has picked up a Breakthrough Therapy designation in the US for the treatment of certain forms of breast cancer.
read article 



CVS Cuts Coverage of Dozens of Drugs in Exclusion Expansion

(Bloomberg) Aug 2, 2016 - It’s the first time that brand-name cancer drugs have been taken off CVS’s standard formulary.
read article 



Novartis CDK4/6 Inhibitor LEE011 (ribociclib) Receives FDA Breakthrough Therapy Designation as First-line Treatment for HR+/HER2- Advanced Breast Cancer

(Novartis) Aug 3, 2016 - Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to LEE011 (ribociclib), in combination with letrozole, for the treatment of hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. LEE011 is a selective cyclin dependent kinase (CDK4/6) inhibitor.
read corporate press release 



Merck’s KEYTRUDA® (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1

(MarketWatch) Aug 2, 2016 - Merck, known as MSD outside the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, at a dose of 2 mg/kg every three weeks, for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen.
read article 



Foundation Medicine Pursuing Parallel Review by FDA, CMS for FoundationOne

(GenomeWeb) Aug 2, 2016 - Foundation Medicine has decided to submit its next-generation sequencing cancer profiling test FoundationOne for parallel review by the US Food and Drug Administration and the Centers for Medicare and Medicaid Services.
read article (free registration required) 



Express Scripts Says Valeant, Lilly, Bristol Drugs To Lack Coverage

(Reuters) Aug 1, 2016 - Express Scripts Holding Co said on Monday it would add a handful of medicines in 2017 to its list of drugs that are excluded from insurance coverage, including treatments for arthritis and psoriasis, while several other medicines will be removed from the exclusion list.
read article 



Skeptical Reaction At Theranos' Coming Out Party

(CNN) Aug 2, 2016 - Theranos CEO Elizabeth Holmes made a first-ever presentation at a scientific conference; the chemistry association said it anticipated the interest and the controversy; the new product Holmes introduced is a kind of miniature lab.
read article 



The ‘Gouge Factor’: Big Companies Want Transparency In Drug Price Negotiations

(STAT/Pharmalot View) Aug 2, 2016 - The path that prescription drugs take from the lab to your medicine chest is a long and complicated one. And the journey is made still more complex by the role of a very important, but little understood middleman known as the pharmacy benefits manager.
read article 



FDA-Approved Knock-Offs Of Biotech Drugs Could Safely Save Big Bucks

(NPR/Shots blog) Aug 1, 2016 - Copycat versions of biotech drugs work just as well as the originals and cost a lot less, according to an analysis of studies of the medicines.
read article 



DuPont 'Acted With Malice,' Says Jury in Cancer Lawsuit

(Medscape Medical News) Aug 2, 2016 - A jury awarded $5.6 million in damages to a man who blames his testicular cancer on drinking water contaminated with DuPont's chemicals.
read article (free registration required) 



St Vincent's Hospital Failed To Act On Dr John Grygiel's Chemo Dosing Errors, Report Reveals

(The Sydney Morning Herald [Australia]) Aug 2, 2016 - A senior staff member has lost their job as a scathing report found St Vincent's hospital misled the public and the government over the chemotherapy dosing scandal, as the total number of patients underdosed by a single oncologist is expected to rise.
read article 



CCS Oncology Patients Face Stress Of Switching Cancer Doctor Or Insurer

(Buffalo News) Aug 1, 2016 - Nearly 600 patients now receiving treatment from CCS Oncology learned the insurer would drop the practice’s 22 oncologists from its network of providers as of Jan. 1.
read article 



Cure Forward Selects Personal Genome Diagnostics as a Provider of Genomic Data to Cancer Patients Using Its Platform to Access Precision Medicine Treatment Options

(The Business Journal) Aug 2, 2016 - Cure Forward and Personal Genome Diagnostics Inc., a provider of advanced cancer genome testing products and services, today announced an agreement that will enable cancer patients using the Cure Forward Patient Activation platform to select PGDx as their genomic testing service provider.
read article 



Evelo Biosciences and Mayo Clinic Establish Research Collaboration for Immuno-microbiome Cancer Therapies

(TheStreet) Aug 2, 2016 - Evelo Biosciences today announced it has entered into an exclusive collaboration with Mayo Clinic investigators to advance immuno-microbiome-based therapies for cancer.
read article 



Regeneron and Adicet Bio Announce Strategic Collaboration to Discover and Develop Next-Generation Engineered Immune Cell Therapeutics

(Yahoo! Finance) Aug 2, 2016 - Regeneron Pharmaceuticals, Inc. and Adicet Bio, Inc. announced today a collaboration and licensing agreement to develop next-generation engineered immune cell therapeutics.
read article 



IBM Says New Chip Can Filter Blood For Signs Of Cancer

(Fast Company) Aug 1, 2016 - IBM today announced technology to build a new "lab-on-a-chip" device that can sort out particles down to the size of exosomes—packets of protein, RNA, and sometimes DNA, ejected from cells, that can hold signs of cancer.
read article 



Eisai, NHS and NICE Fail To Reach Deal On Lenvima

(PharmaTimes [UK]) Aug 2, 2016 - Patients with an advanced form thyroid cancer may have to wait three years for NHS access to Eisai's Lenvima in England, after the drug was left out of the newly launched Cancer Drugs Fund.
read article 



FDA Seeking Applicants for its Patient Representative Program

(ASCO in Action) Aug 1, 2016 - The U.S. Food and Drug Administration (FDA) is currently seeking applicants for its FDA Patient Representative Program for several disease areas, including cardiovascular disease, sarcoma, thyroid and bladder cancer.
read article 



Community Oncology Alliance Announces Major Support Initiative for CMS Oncology Care Model

(COA) Aug 2, 2016 - The Community Oncology Alliance (COA) has launched a major support initiative effort behind the Centers for Medicare & Medicaid Services (CMS) Innovation Center's (CMMI) oncology payment and delivery reform initiative, the Oncology Care Model (OCM).
read press release 



A Cancer Cell’s Achilles Heel

(Tufts University/Tufts Now) Aug 1, 2016 - Tufts researcher is targeting a mechanism that allows cancer to spread.
read article 



One of the Most Common Viruses in Humans May Promote Breast Cancer Development

(BIDMC) July 29, 2016 - New research reveals that infection with the Epstein–Barr virus (EBV) may put some women at increased risk for developing breast cancer. The findings, published online in the July issue of the journal EBioMedicine, may have important implications for breast cancer screening and prevention.
read press release 



Stem Cells May Speed Up Screening of Drugs for Rare Cancers

(Johns Hopkins) Aug 1, 2016 - Researchers at the Johns Hopkins Kimmel Cancer Center say they have developed a system that uses transformed human stem cells to speed up screening of existing drugs that might work against rare brain and other cancers.
read press release 



Rare Genetic Variant May Predict Barrett Esophagus, Esophageal Cancer

(Healio) Aug 1, 2016 - Mutations in the VSIG1OL gene appeared associated with susceptibility to familial Barrett esophagus and esophageal cancer, according to study results published in JAMA Oncology.
read article 



Amgen And Advaxis Enter Global Cancer Immunotherapies Collaboration

(Amgen) Aug 2, 2016 - Amgen and Advaxis, Inc. today announced a global agreement for the development and commercialization of Advaxis' ADXS-NEO, a novel, preclinical investigational cancer immunotherapy treatment that is designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor.
read corporate press release